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Introduction 
According to Pierre Bourdieu, we can explain the impact and outcome of social actions by 
looking at how agents act under societal rules and structures which are in the field that the 
agent operates within1. Bourdieu’ thoughts and concepts inspire a type of investigation, where 
one has to gather data about both the field which the agent operates within and the measures 
that the agent uses to achieve his goals. By doing so it can be described how an agent acts and 
shapes his environment through his social actions. This dualism between agent and structure is 
what constructs our social reality2. Therefore it is necessary to investigate both agent and 
structures in order to explain consequences of social action. This is the philosophy which has 
inspired the following project.   
 
Problem Area 
In the United States, citizens are exposed to many different kinds of commercials on a daily 
basis. There are several ways for commercials to reach the citizens, such as TV channels, the 
radio, newspapers, and the internet. In the United States (US), advertisements are not only 
consisting of commercials with products such as make-up, clothes, or food, but there are also 
commercials with prescription drugs, commercials which are called Direct to Consumer 
Advertisements (DTCA). The pharmaceutical industry is investing a lot of money on this kind 
of marketing3. Pharmaceutical companies are using DTCAs to create an awareness of possible 
diseases people could have and at the same time presenting the products which can treat the 
diseases. This is a common way for pharmaceutical companies to market their products in the 
US. Other ways, by which the companies promote their products, is by promotional meetings, 
professional detailing, promotional mailings, free samples etc. The pharmaceutical industry 
has been steadily increasing in the United States through the last couple of decades and it is the 
biggest industry, with the largest profits, as seen in the following figure4: 
                                                          
1 Walther M. (2014): 7-16 
2 Walther M. (2014): 7-16 
3 Statistica: “Share of promotional spending of top 20 pharmaceutical companies in the U.S. by allocation in 
2013”, http://www.statista.com.molly.ruc.dk/statistics/388002/promotional-spending-allocation-from-top-20-
pharma-companies-in-the-us/ [Accessed: 27th November 2015]. 
4 Liyan, Chen (2015): “The Most Profitable Industries In 2015”, 
http://www.forbes.com/sites/liyanchen/2015/09/23/the-most-profitable-industries-in-2015/, [Accessed: 27th 
November 2015]. 
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Figure. 1 - The Most Profitable Industries In 2015 
The industry’s growth and marketing tactics has been heavily debated5. Critics are saying that 
the pharmaceutical industry is regulating the prices according to what drugs is mostly 
prescribed and the pharmaceutical companies are then taking a higher price for these to gain 
more profit. They also argue that the pharmaceutical giants are investing too little on research 
and development of the drugs, compared to the funds used for marketing and administration. 
Furthermore, critics are saying that the advertisements are creating a demand for brand name 
drugs, instead of having people buying less costly generic drugs which have the same effect6. 
Proponents argue that the pharmaceutical companies’ marketing is informative, educative, and 
are empowering people. They argue that DTCAs gives the consumers the opportunity to not 
only have knowledge given from the doctor but also with these advertisements, people have 
the possibility to have information from other sources. They are also arguing that the 
advertisements have a form of ‘commercial speech’ and to ban or restrict DTCAs would violate 
the First Amendment, which is the right to freedom of speech.  
Due to this controversy, some states have restricted and banned some of the pharmaceutical 
industries’ marketing methods. The industry wants to continue marketing and is therefore 
                                                          
5 Center for Responsive Politics: “Pharmaceuticals / Health Products”, 
http://www.opensecrets.org/industries/background.php?cycle=2014&ind=H04 [Accessed: 11th November 2015]. 
6 Brown H. (2010): p. 11 
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spending a lot of money to pay politicians and federal organizations to loosen the federal 
restrictions and ensure that no new bills are getting passed which can hinder the ability of the 
pharmaceutical industry in promoting their products7. 
With regard to this controversy I have chosen to investigate the following - Research Question 
(RQ) 
“How has the pharmaceutical industry been using Direct To Consumer Advertisements to 
promote their products and what are the consequences of this promotion strategy?”  
 
I have chosen the following sub-questions to guide my research and these questions will later 
enable me to discuss my RQ. 
1) What are the laws around the pharmaceutical industry’s marketing? 
2) What is the pharmaceutical industry’s capacity to influence these laws? 
3) How is the pharmaceutical industry using this capacity? 
4) How has consumers responded to the promotion strategy? 
Question one allows me to investigate the structures and laws around the industry’s 
marketing. Question two allows me to investigate the capacity that the industry has to 
influence the law-making process. Question three enables me to get knowledge on how the 
industry are promoting their products within the current laws and question four gives me 
insight into some of the consequences of this promotion strategy. This process will ultimately 
make me able to discuss and provide conclusions to the above stated RQ. 
 
 
 
 
 
 
                                                          
7 Open Secrets (1998-2015): “Top Industries”, http://www.opensecrets.org/lobby/top.php?indexType=i   
[Accessed: 27th November 2015]. 
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Project Outline 
 
Chapter 1, introduction 
This chapter introduces the background and reasoning for my RQ: “How has the 
pharmaceutical industry been using Direct To Consumer Advertisements to promote their 
products and what are the consequences of this promotion strategy?”  
Chapter 2, Theory 
In this chapter, I will present Pierre Bourdieu’s theory of social practice, and explain the 
concepts of field, habitus, and capital, which I will use as tools for analysing how the 
pharmaceutical industry are promoting and what the consequences are of this promotion. 
Chapter 3, methodology 
In this section I will explain my research design. Here I explain why I chose Bourdieu and how 
I will be using theory and data to discuss my research question. I will also comment on the 
reliability and validity of what I have found in my project, and the limitations of the project. 
Chapter 4, Pharmaceutical marketing in the US 
In this chapter I will be presenting information on the laws related to marketing practice in the 
United States. I will describe the lobbying of pharmaceutical companies to influence the law 
making process. I will present examples of pharmaceutical companies’ marketing efforts and 
lastly how consumers have responded to these efforts.  
Chapter 5, Analysis and Discussion 
In this chapter I will use Bourdieu’s concepts to analyze the pharmaceutical companies’ 
promotion efforts, by discussing the laws of marketing, the pharmaceuticals companies’ 
capabilities of promotion and how the pharmaceutical companies use different forms of capital 
in their promotion.  
Chapter 6, Conclusion and Perspectivation 
In this chapter, I will conclude on my RQ, as a result of my analysis and discussion. I will make 
a short perspectivation on further investigations that could be of interest with regard to my 
project. 
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Theoretical Framework 
Theory of Practice 
Bourdieu’s theory of practice is an abstract and normative theory that can be, and have been, 
applied to research in several fields such as Organizational Studies, Human Resource 
Management and Marketing8. It can be used, to analyse the success and domination of social 
actors in terms of their resources and the use of these resource in pursuing interest. The theory 
is an attempt to reconcile the dualism between structure and agency or structuralism and 
constructivism9. According to Bourdieu, structures are rules which determine and condition the 
agents’ behaviours10. On the other hand, agents are completely free in their choices and can act 
according to a vast array of alternatives that are not bound by rule or structure11. Bourdieu 
attempts to deal with this problematic duality by the concepts of field, habitus and capital12. 
Bourdieu understand a field as a place where rules and agents meet and which has to be 
examined by empirical research13. Because there are several fields and fields are sometimes 
overlapping, for instance; politics are sometimes influenced by economics, religion or popular 
opinion, or the search for clean energy might be influenced by what is technologically realistic 
etc. In a social field agents and structures meet and agents battle to maximize their respective 
capital14. So the field is consisting of rules which Bourdieu calls Illusio and the agent has a 
certain capacity to act within these rules to gain capital advantage, this is referred to as the 
agents’ Doxa15. The capacity that the agent has to influence his position on the field can be 
described by four different types of capital – Economic, Social, Cultural, and Symbolic. With 
these types of capital Bourdieu emphasizes the active role of the agent in the construction of 
the social reality16. 
In the cultural capital he finds three other semblances; the embodied state, the objectified state, 
and the institutionalized state. Cultural capital in the embodied state is qualities which one has 
received through one life such as; piano skills, reading skills, knowledge etc. It can either be 
                                                          
8 Walther M. (2014): p.7 
9 Walther M. (2014): p.7 
10 Walther M. (2014): p.7 
11 Walther M. (2014): p.7 
12 Walther M. (2014): p.7 
13 Walther M. (2014): p.8 
14 Walther M. (2014): p.9 
15 Walther M. (2014): p.9 
16 Walther M. (2014): p.12 
First Semester Project 
Sasha Scheele Sandberg 
Group 28 
 
7 
 
7 
skills, which has been acquired and internalized since childhood, or it can be through life 
experience. Cultural capital in the objectified state, are objects/material which one has gathered 
e.g. books, technology, clothes etc. Cultural capital in the institutionalized state takes the form 
of titles which one has achieved through accomplishments, and can be gained through 
connections or education, e.g. the title of a doctor, of a snob, of a joyful person etc. All these 
three forms of cultural capital combined is one’s cultural capital.17 
Social capital is relations which one creates and this capital gives the potential to access other 
kinds of capital. Social capital is a form of network which can give access to potential and 
actual resources such as knowledge, information, material or immaterial resources. Social 
capital can be institutionalized in a form of title that requires an effort to maintain, such as titles 
of nobility or job titles which open up for a network of connections and thereby potential 
resources18. 
Economic capital is the fortunes one possess and it can be institutionalized in the form of a 
binding contract of ownership19. This type of capital is easily converted into other forms, such 
as exchanging money for a book, which would be transferring economic capital for objectified 
capital, and if that book becomes read it would then become embodied capital etc. 
Symbolic capital can be said to the sum of all attained capitals. It is the recognition by agents 
and the system that acquiring various forms of capital are desirable20. In other words; if 
something is desirable it has symbolic capital.   
The last of Bourdieu’s concepts is Habitus. According to Bourdieu: 
“(…) habitus is the result of social structures, more precisely of the social class 
(doxa) and the rules of the game on the field that have been internalized (illusion)”21 
Habitus is the unconscious practice that guides our practice or strategy to achieve our 
objectives. It is the way we are predisposed to act within a field and the way we act are also 
determined by the capital at our disposition. The interplay of Habitus, Field and Capital are 
                                                          
17 Bourdieu P. (1986): p. 1-15 
18 Walther M. (2014): p.10 
19 Walther M. (2014): p.10 
20 Walther M. (2014): p.10 
21 Walther M. (2014): p.14, l. 12-13 
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the elements that lead to strategy or practice that aims at achieving our objectives by 
investing capital and fighting for capital22.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
22 Walther M. (2014): p.15 
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Methodology 
In this section, I will present the research design and the choice of theoretical frame, validity, 
reliability and generalization, limitations, and data collection.  
 
Research Design & Bourdieu as Theoretical Frame 
The purpose of this project is to describe how the pharmaceutical companies are using different 
forms of capital in the United States (US) and what consequences this process can bring about. 
I have chosen a deductive approach where I use theoretical concepts as tools for researching 
data23. Therefore the research aim is to use Bourdeus’ concepts to understand and describe how 
pharmaceutical companies use their disposable forms of capital to promote their products.  
According to Bourdieu we can explain the practice of agents by describing the field and the 
habitus as a consequence of the capitals that pharmaceutical companies invest in the promotion 
of their products. This process can be seen in the following model24.  
 
Figure 2: Social Practice as Theoretical Frame 
                                                          
23 Bryman A. (2008): p.9 
24 Walther M. (2014): p.16 
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In order for me to discuss this process and its possible consequences, I will first describe the 
field which in this project is the pharmaceutical industry. Then I will describe the ‘rules of the 
game’ or structures which in this project is represented by Politicians and the Food and Drug 
Administration (FDA). Then I will investigate the various forms of capitals that the 
pharmaceutical companies have at their disposal to promote their products. Lastly, I will 
present examples on how the pharmaceutical industry has promoted their products, thereby 
allowing me to examine the actual practice or strategy by which the pharmaceutical industry 
uses its disposable capital for promotion25. The argument for using Bourdieu in this project is 
that his concepts allow me to describe social practice as a result of invested capital, but also 
how this practice influence structures in society – thereby enabling me to discuss the possible 
consequences of the pharmaceutical companies’ promotion efforts as an outcome of the 
invested capitals. 
 
Validity, Reliability and Generalization 
The validity of this projects’ findings depends on my own ability to use Bourdieu’s concepts 
to analyse, interpret and discuss the data presented in the chapters in this project26. The 
reliability of my approach can be said to be somewhat reliable when it comes to theory, other 
researchers who use Bourdieu’s concepts might find some of the same capitals invested and 
some of the same structures affected etc27. On the other hand it is doubtful that other researchers 
would use the same data that I have found, thereby making the approach less reliable. The 
findings in this report cannot be used to generalize from28. The focus is only on the 
pharmaceutical industry in the U.S and this large subject is far too broad and different, both 
within the U.S and abroad. For instance, the U.S is one of the only countries where 
pharmaceutical companies are allowed to advertise direct to consumers and not all countries 
have lobbying practices. All in all; it can be said that my project very much depends on my 
own interpretations and choice of data, but since this is my 1st semester project my aim has 
been to learn how I could use theory to investigate a subject in a problem-orientated manner. 
                                                          
25 Walther M. (2014): p.16 
26 Bryman A. (2008): p.151 
27 Bryman A. (2008): p.149 
28 Bryman A. (2008): p.649 
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Limitations 
There lots of data, which can be used to describe or analyse the pharmaceutical industry, but I 
have chosen to limit myself to the data presented in this projects’ chapters to answer my 
research-question. I investigate the pharmaceutical promotion practice within the U.S. I have 
also chosen to focus on Direct To Consumer Advertisements (DTCA), instead of looking at all 
of the different ways for pharmaceutical companies to promote their products.   
 
Data Collection 
My data consists of secondary data from websites in the form of: journals, articles, and 
statistics. I have used information from the Food and Drug Administration’s own website, to 
access the actual regulations and precise descriptions of these. I have used information from 
the World Health Organisation (WHO), Forbes, the New York Times, Center for Responsive 
Politics, Business Insider, The Pew Charitable Trusts, National Conference of State 
Legislature, and more. The statistics is from Cegedim Strategic Data, which is one of the 
leading market research companies in the world and it is dedicated to monitor the healthcare 
industry. All of these websites are considered quite accurate and trustworthy in their accounts. 
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Pharmaceutical Marketing in the US 
In this section, I will present the types of marketing, laws and guidelines in the pharmaceutical 
industry, the lobbying in the pharmaceutical industry, come with examples of marketing 
campaigns, and describe the consequences of Direct To Consumer Advertisements.  
 
Types of Marketing 
In the United States, the pharmaceutical companies can market in different ways compared to 
other countries. 
 
Figure. 3: Cegedim Strategic Data, U.S. Pharmaceutical Company Promotion Spending (2012)29.  
They can market with Direct To Consumer Advertisements (DTCA), which is only legally 
allowed in the US and in New Zealand. They can also market with detailing, which is where a 
pharmaceutical representative promotes the product, typically by visiting doctors. The detailing 
can include meals and gifts given to the doctor. Then the companies use samples, which they 
give to physicians that then gives them to the consumers in order to create awareness of the 
drug and its effectiveness. They also use money on educational and promotional meetings, 
                                                          
29 The PEW charitable trusts: “Persuading the Prescribers: Pharmaceutical Industry Marketing and its 
Influence on Physicians and Patients”, http://www.pewtrusts.org/en/research-and-analysis/fact-
sheets/2013/11/11/persuading-the-prescribers-pharmaceutical-industry-marketing-and-its-influence-on-
physicians-and-patients [Accessed: 16th November 2015]. 
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where a sales representative invite doctors and/or physicians over to a meal paid by the 
pharmaceutical company to discuss the matter of drugs. Some companies also market with 
promotional mailings, that are send to doctors about a particular drug, and sometimes also to 
consumers30.  
 
Laws and Guidelines in the Pharmaceutical Industry 
Within the pharmaceutical industry, there are some laws, which regulate what kinds of 
marketing is allowed and what kind of marketing that is not. There are in the “Code on 
Interactions with Healthcare Professionals”, by PhARMA, some guidelines for how 
pharmaceutical companies should behave when marketing their products, they are described 
as:  
“Our relationships with healthcare professionals are regulated by multiple entities and 
are intended to benefit patients and to enhance the practice of medicine. Interactions should 
be focused on informing healthcare professionals about products, providing scientific and 
educational information, and supporting medical education. Promotional materials provided 
to healthcare professionals by or on behalf of a company should: (a) be accurate and not 
misleading; (b) make claims about a product only when properly substantiated; (c) reflect the 
balance between risks and benefits; and (d) be consistent with all other Food and Drug 
Administration (FDA) requirements governing such communications”31.  
These guidelines are to be applied on the pharmaceutical industry’s marketing. If the materiel 
provided is not accurate and is misleading, it is violating a primary statue called Federal False 
Claims Act (FCA) from 1863, and it is violated when a person (or if causing another person 
to) knowingly making a false claim32. In 2010 President Barack Obama signed a bill that made 
further amendments to this FCA bill and the bill was called the health reform bill. One of the 
amendments was the Anti-kickback statute, which requires that anyone (the pharmaceutical 
company) that has made a claim which is not adequate, can be convicted even when the 
                                                          
30 The PEW charitable trusts: “Persuading the Prescribers: Pharmaceutical Industry Marketing and its 
Influence on Physicians and Patients”, http://www.pewtrusts.org/en/research-and-analysis/fact-
sheets/2013/11/11/persuading-the-prescribers-pharmaceutical-industry-marketing-and-its-influence-on-
physicians-and-patients [Accessed: 16th November 2015]. 
31 PhARMA 2008: p. 4, l. 2-11 
32 Legal Information Institute: “31 U.S. Code § 3729 - False claims”, 
https://www.law.cornell.edu/uscode/text/31/3729 [Accessed: 12th November 2015]. 
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company has made the claim ‘unknowingly’. Furthermore, the health reform bill requires that 
anyone (pharmaceutical companies and their representatives) cannot give something of value 
(meals, gifts; pens, pads, logo bags etc.) in exchange for receiving certain services (e.g. having 
doctors prescribing the product). The knowledge given out about the product must also be 
consistent and approved by the Food & Drug Administration (FDA)3334. PhARMA’s 
guidelines, also states:  
“In order to provide important scientific information and to respect healthcare 
professionals’ abilities to manage their schedules and provide patient care, company 
representatives may take the opportunity to present information during healthcare 
professionals’ working day, including mealtimes. In connection with such presentations or 
discussions, it is appropriate for occasional meals to be offered as a business courtesy to the 
healthcare professionals as well as members of their staff attending presentations, so long as 
the presentations provide scientific or educational value and the meals (a) are modest as 
judged by local standards; (b) are not part of an entertainment or recreational event; and (c) 
are provided in a manner conducive to informational communication”35. 
These are only guidelines and are therefore not to be considered laws. Different states in the 
U.S have different laws requiring that some of these guidelines are followed. If they are not 
followed, the different states have different means of punishments for the companies.  
Another act that has made a lot of influence on the pharmaceutical industry is the 1992 
Prescription Drug User Fee Act, which consents pharmaceutical companies to help fund the 
new drugs approval process. Director of Public Citizen's Health Research Group, Sidney Wolf, 
is saying that this act meant that the FDA started looking at the pharmaceutical companies as 
                                                          
33 Legal Information Institute: “42 U.S. Code § 1320a–7b - Criminal penalties for acts involving Federal health 
care programs”, https://www.law.cornell.edu/uscode/text/42/1320a-7b [Accessed: 12th November 2015]. 
34 Johnson Ken (2008): “Doctors: Stop Taking Pharma Gifts”, 
http://www.businessweek.com/debateroom/archives/2008/04/doctors_stop_taking_pharma_gifts.html#share  
[Accessed: 12th November 2015]. 
35 PhARMA (2008): p. 4, l. 20-30 
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their client36. Proponents for this law are saying that the act is to increase the drug approval 
processes so that patients can get drugs faster37.  
Direct To Consumer Advertisements (DTCA), however are more complex and there are rules 
around these advertisements for all states. DTCA are the type of advertisement you can usually 
find on these following media; television, magazines, newspapers, radio, internet, and in the 
cinema, but also brochures given to doctors, to give to their patients, are considered DTCA38. 
The FDA had made some regulations that were finished in 1969, which required that an 
advertisement: 
“must (1) not be false or misleading, (2) present a “fair balance” of information 
describing both the risks and benefits of a drug, (3) include facts that are “material” to the 
product’s advertised uses, and (4) include a “brief summary” that mentions every risk 
described in the product’s labeling”39.   
See ‘Glossary’, for the terms: ‘fair balance’ and ‘brief summary’.  
In the 1980’s the pharmaceutical industry were becoming more acknowledged and that caused 
a change in the society with patients taking a more active role in deciding whether to medicate 
or not, together with their doctor. At the same time, the DTCAs were becoming more and more 
frequent, as a response to these changes. During the mid-80’s and into mid-90’s, it was debated 
whether or not these rules were sufficient, where some thought that the prohibitive time and 
the money that the rules required were too harsh on the pharmaceutical companies. It was in 
1997 that the FDA then changed the laws around DTCAs into allowing broadcasting DTC 
product claim advertisements, where it did not need to mention all the products risks in the 
“brief summary”, but only needed to mention the “major risks”, in order to make an “adequate 
provision” with the “major statement”. The advertisement should also explain where to get a 
complete “brief summary” of the products risks, with a number to call, a specific health care 
provider, the internet or other ways to get more information40. In 2004 the FDA again changed 
                                                          
36 Sidney Wolf: “How independent is the FDA?”, 
http://www.pbs.org/wgbh/pages/frontline/shows/prescription/hazard/independent.html [Accessed: 24th 
November 2015]. 
37 FDA: “PDUFA Legislation and Background”, 
http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm144411.htm [Accessed: 24th November 
2015]. 
38 WHO (2009): “Direct-to-consumer advertising under fire”, http://www.who.int/bulletin/volumes/87/8/09-
040809/en/ [Accessed: 26th November 2015]. 
39 C. Lee Ventola 2011: p. 670, l. 16-22 
40 see ‘Glossary’ for detailed description on terms 
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the laws, into that the product claim advertisement only needed a “simplified brief summary”, 
with only explaining the “major risks”, but now in a simplified language that the viewer could 
understand41.  
These are the three types of advertisements, which all have to meet the regulatory requirements 
by the FDA (U.S. Food and Drug Administration), and these are the latest updates;  
Type of advertisement Requirements 
The product-claim advertisement: “A 
product claim ad names a drug, says what 
condition it treats, and talks about both its 
benefits and its risks. An ad must present the 
benefits and risks of a prescription drug in a 
balanced fashion. Balance depends on both 
the information in the ad itself and how the 
information is presented. In this ad, the 
benefits and risks are presented to give a 
balanced impression of the drug”42. 
The advertisement has to mention, at least 
one approved use of the drug, and the generic 
name of the drug. It has to have a “fair 
balance” where in the risks should be the 
“simplified brief summary”. Or if it is a 
broadcasting advertisement, the risks have to 
be in the “major statement”, where “adequate 
provision” shall be included to have access 
to the “brief summary”43. 
The reminder advertisement: “Reminder 
ads give the drug's name but not the drug's 
use. The assumption behind reminder ads is 
that the audience knows what the drug is for 
and does not need to be told”44. 
The advertisement cannot mention how to 
treat the disease, the brand name, and the 
generic name45. 
                                                          
41 C. Lee Ventola (2011): “Direct-to-Consumer Pharmaceutical Advertising”, p. 670 
42 FDA: “Product Claim Ad (Correct)”, 
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/PrescriptionDrugAdvertising/ucm082284.htm 
[Accessed: 14th November 2015]. 
43 FDA: “Product Claim Ad (Correct)”, 
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/PrescriptionDrugAdvertising/ucm082284.htm 
[Accessed: 14th November 2015]. 
44 FDA: “Reminder Ad (Correct)”, 
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/PrescriptionDrugAdvertising/ucm083573.htm 
[Accessed: 14th November 2015]. 
45 FDA: “Reminder Ad (Correct)”, 
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/PrescriptionDrugAdvertising/ucm083573.htm 
[Accessed: 14th November 2015]. 
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The help-seeking advertisement: “Help-
seeking ads describe a disease or condition 
but do not recommend or suggest specific 
drugs. (…) Help-seeking ads may include a 
drug company's name and may also provide 
a telephone number to call for more 
information”46. 
In this advertisement, there are no claims 
made and neither is the product mentioned. 
A “fair balance”, “brief summary”, and 
“adequate provision” are therefore not 
required47. 
 
There is no law saying that pharmaceutical companies have to send in their advertisements 
before they are used, though when the advertisement has been used, the company has to send 
in the advertisement to the FDA, for them to regulate it48.  
These DTCA does not have to tell you:  
- how much the drug costs 
- that there are another generic versions of the drug that are could be cheaper 
- that there is another similar drug with less risks and side-effects 
- that the drug might not be needed if a change in behavior would just as efficient (eat 
healthier, work-out etc.), though sometimes it is needed but it depends on the drug 
- the amount of people that been treated by the drug 
- the way the drug works 
- the amount of people that has taken the drug, that has been helped by it 
- the amount of time it takes before the drug starts working (though if the advertisement 
says the drug works quickly, it has to explain what that means)49 
The pharmaceutical companies have to consent with FDA regulations, because if the FDA 
regulations are not met, there are consequences for the pharmaceutical company. If an 
                                                          
46 FDA: “Correct Help-Seeking Ad”, 
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/PrescriptionDrugAdvertising/ucm082288.htm 
[Accessed: 17th November 2015]. 
47 C. Lee Ventola (2011): p. 669 
48 FDA: “Prescription Drug Advertising: Questions and Answers”, 
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/PrescriptionDrugAdvertising/ucm076768.htm#control
_advertisements [Accessed: 17th November 2015]. 
49 FDA: “Prescription Drug Advertising: Questions and Answers”, 
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/PrescriptionDrugAdvertising/ucm076768.htm#control
_advertisements [Accessed: 17th November 2015]. 
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advertisement does not follow the laws, the consequences are usually that the pharmaceutical 
company gets a warning letter, where it e.g. asks the pharmaceutical company to withdraw the 
advertisement. However, if these requirements written in the warning letter are not met, the 
pharmaceutical company can be taken to court and pressed charges50. 
 
Lobbying in the Pharmaceutical Industry 
When pharmaceutical companies are marketing, they have to act within the laws described, but 
pharmaceutical companies also want to influence the laws in order for e.g. politicians not 
banning DTCA, as seen in some states51. The industry are spending a lot of money lobbying to 
politicians, FDA and other federal agencies and it is the industry that spends most on lobbying, 
as seen in the following figure: 
 
Figure 4: Top industries
52 
The pharmaceutical industry is spending money on lobbying to influence legislation, 
lawmakers and politicians and their policy aims is: to resist the government-run health care, 
                                                          
50 FDA: “Prescription Drug Advertising: Questions and Answers”, 
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/PrescriptionDrugAdvertising/ucm076768.htm#control
_advertisements [Accessed: 17th November 2015]. 
51 NCSL: “Marketing and Direct-to-Consumer Advertising (DTCA) of Pharmaceuticals” 
http://www.ncsl.org/research/health/marketing-and-advertising-of-pharmaceuticals.aspx [Accessed: 26th 
November 2015]. 
52 Center for Responsive Politics: “Top Industries”, 
http://www.opensecrets.org/lobby/top.php?showYear=2015&indexType=i [Accessed: 28th November 2015]. 
Industry  Total 
Pharmaceuticals/Health Products  $178,863,490 
Insurance  $118,590,460 
Oil & Gas  $97,312,188 
Business Associations  $96,916,665 
Electronics Mfg & Equip  $91,207,890 
Electric Utilities  $88,114,214 
Misc Manufacturing & Distributing  $80,737,065 
Health Professionals  $73,453,376 
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ensure a quick approval process for drugs that are entering the market and make its intellectual 
property protection stronger53. 
Big pharmaceutical companies are usually spending more money on Republicans than on 
Democrats, as for example, Big Pharma spend in 2012, 58 % of the industries federal 
contributions on the Grand Old Party (GOP), where they only spend 42 % in 201454. The Big 
Pharma company Pfizer spend in 2014 at the elections $1.5 million on federal campaign 
contributions, as the top spender, with the following companies Amagen spending $1.3 million 
and McKesson Corp spending $1.1 million. These Big Pharma companies were all spending 
more on Republicans than Democrats in that election. This is due to, that Republicans have 
been keener to collaborate with the pharmaceutical companies than Democrats have55.  
Pharmaceutical companies are also influencing the FDA and have lobbied progressively to get 
a bill passed through, called 21st Century Cures Act, that would ensure less randomized 
controlled trials, which has been the main marker when deciding if a new drug is safe or not. 
The bill were passed through in April 2014, and means the main indicator, which determines 
how safe the drug is, is relied less on and that, there will be more focus on other areas such as 
“clinical experience”, which e.g. is observational study56. This is only one bill which the 
pharmaceutical industry has lobbied for and some critics has also pointed out that the FDA is 
cooperating too closely with the pharmaceutical industry. President Obama has nominated a 
candidate to lead the FDA, Dr. Robert Califf, from Duke University’s, who is Vice Chancellor 
for clinical research, whom has worked very close with the pharmaceutical industry. Califf 
were in May 2015, presenting to an audience of executives, that the FDAs regulations are 
necessary, except that it is “too slow and too expensive and required disruption and 
transformation”57, and “Towards the end of his talk, he put up a slide that identified a key 
                                                          
53 Center for Responsive Politics: “Pharmaceuticals / Health Products: Background”, 
http://www.opensecrets.org/industries/background.php?ind=H04++ [Accessed: 28th November 2015]. 
54 Trouthout: “How Much of Big Pharma's Massive Profits Are Used to Influence Politicians?” 
http://www.truth-out.org/news/item/33010-how-much-of-big-pharma-s-massive-profits-are-used-to-influence-
politicians [Accessed: 12th November 2015]. 
55 Center for Responsive Politics: “Pharmaceuticals / Health Products”, 
http://www.opensecrets.org/industries/background.php?cycle=2014&ind=H04 [Accessed: 11th November 2015]. 
56 Center for responsive Politics: “PhRMA companies push hard on House bill to ease testing of new drugs”, 
https://www.opensecrets.org/news/2015/06/phrma-companies-push-hard-on-house-bill-to-ease-testing-of-new-
drugs/ [Accessed: 18th November 2015]. 
57 TIME 2015: “Candidate to Lead FDA Has Close Ties to Big Pharma”, http://time.com/3714242/candidate-
to-lead-fda-has-close-ties-to-big-pharma/ [Accessed: 13th November 2015]. 
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barrier to change: regulation”58. Dr. Robert Califf, were also before working for the FDA, a 
consultant and a board member at Faculty Connection, which is a company who helps 
pharmaceutical companies “evade and manipulate FDA regulations”59. He has received $ 
100.000 every year for consulting pharmaceutical companies, where FDA claims that he uses 
that money on nonprofits. Califf have stated to TIME that it is: “useful to have someone 
[leading the FDA] who understands how companies operate because you’re interacting with 
them all the time”60. This nominee has been criticized for having a too close relationship with 
the pharmaceutical industry, and Dr. Robert Califf is only one example of how the 
pharmaceutical industry is corroborating closely with the FDA and there are many other 
examples, which shows this collaboration.  
 
Examples of Marketing Campaigns 
 
Shire is a global biopharmaceutical company that is founded in the United Kingdom, but has a 
big operative base in Untied States. It is a company, 
which specializes in rare diseases and other 
specialty conditions, such as ADHD. One of this 
pharmaceutical company’s ways to market in the 
United States is by DTCA as seen by the poster in 
the right side61.   
                                                          
58 TIME (2015): “Candidate to Lead FDA Has Close Ties to Big Pharma”, http://time.com/3714242/candidate-
to-lead-fda-has-close-ties-to-big-pharma/ [Accessed: 13th November 2015]. 
59 TIME (2015): “Candidate to Lead FDA Has Close Ties to Big Pharma”, http://time.com/3714242/candidate-
to-lead-fda-has-close-ties-to-big-pharma/ [Accessed: 13th November 2015]. 
60 Wendler C. (2015): “Obama’s New Appointee to Head the FDA Is a Big Pharma Mega-Lobbyist”, 
http://theantimedia.org/obamas-new-appointee-to-head-the-fda-is-a-big-pharma-mega-lobbyist/ [Accessed: 19th 
November 2015]. 
61 Shire: “Who We Are”, https://www.shire.com/who-we-are [Accessed: 19th November 2015]. 
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ADHD advertisements has first started out with 
targeting parents with troubled children and referred 
to a proper treatment as something that could make 
both parent’s and children’s life easier. However, 
ADHD has become recognized, as a disease that 
does not appear only in children but also continue, 
for some throughout adulthood62. For example are 
pharmaceutical companies also making 
advertisements with celebrities to catch adult’s 
attention toward ADHD. The celebrity has gone 
through the same disease and had success in life, and 
other people can do the same, if they just take the 
medication, which is the medicine that the pharma 
company is selling. Adam Levine is one of the celebrities that Shire has used in their 
advertisements, where he says: “I remember being the kid with ADHD. Truth is, I still have 
it”63. Shire is here targeting adults and is using the band, Maroon 5’s lead singer, Adam Levine 
to promote their drug. The advertisement is a help-seeking advertisement and is advising the 
viewer to take a quiz on the internet, to see if the viewer could have ADHD and that the viewer 
should then talk to a doctor about it64.  
DTCA all have to act within the laws that FDA has made, but sometimes pharmaceutical 
companies are not following them. Shire is one of the pharmaceutical companies which has not 
followed them and they have been sent two warning letters, first in 2000 and then again in 
2008.  
In 2000 Shire were send a letter from the FDA regarding a campaign for the ADHD medicine 
Adderall Tablets. It was the Division of Drug Marketing, Advertising, and Communications 
(DDMAC), which send the letter, as the DDMAC were the department in the FDA that did the 
                                                          
62 American Psychiatric Association 2013: “Attention Deficit/ Hyperactivity Disorder”, American Psychiatric 
Publishing 
63 Buissness Insider 2013: “These Are The Ridiculous Ads Big Pharma Used To Convince Everyone They Have 
ADHD”, http://www.businessinsider.com.au/adhd-medication-marketing-techniques-2013-12 [Accessed: 25th 
November 2015]. 
64 Buissness Insider 2013: “These Are The Ridiculous Ads Big Pharma Used To Convince Everyone They Have 
ADHD”, http://www.businessinsider.com.au/adhd-medication-marketing-techniques-2013-12 [Accessed: 25th 
November 2015]. 
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surveillance and monitoring of DTCAs. The DDMAC had following objections against a 
journal advertisement and a sales advertisement: ‘unsubstantiated comparative claims’ e.g. “On 
average, Adderall is more effective than Ritalin”65, ‘fair balance’, and ‘unapproved uses’66. 
Again, in 2008 Shire got a warning letter, which had objections against a website and a 
YouTube video, because they were overstating the efficacy of the ADHD medicine Adderall 
XR. The YouTube video were with the celebrity Ty Pennington from a TV-show ‘Extreme 
Makeover: Home Edition’, and he said these following sentences which was to overstate the 
efficiency of Adderall XR, in the video: “the medication “literally changed my life” and “gave 
me confidence,””67. The website were overstating the efficiency by making false claims of how 
effective the medicine was and that if ADHD were not treated by this drug it could have all 
kinds of different consequences68. These two warning letters show some campaigns, which 
were not following the requirements put forth by the FDA. 
 
The Consequence of DTCA 
AARP is an organization that is nonprofit and nonpartisan, which produce the magazine AARP 
the Magazine and it has over 31.1 million readers. AARP hired the survey company SSRS, to 
make a telephone survey in 2010, with 1,019 people in the age of 18+. The survey showed that 
91% of the respondents had seen a prescription drug advertisement, while 7% had not seen or 
heard them. The ones who had seen the advertisements where then asked where they had seen 
them, where 78% had seen them on the television, 31% had seen them in magazines, 19% on 
the internet, 16% in newspapers, 14 % in the radio, 14% in the pharmacy, 11% had got them 
on e-mail, 8% had seen them outside, and 8% have got them on direct mail. The respondents 
were then asked if they had gone to the doctor, to ask for a prescription drug after they had 
seen an advertisement, where 10% had gone to the doctor for a prescription drug after they had 
seen an advertisement and 90% had not gone to the doctor for a prescription drug they had seen 
on an advertisement. The 10% that had gone to the doctor were then asked if they had received 
a free sample, if they gotten the prescription drug, if the doctor had said that the medicine did 
not suit the respondent or if the respondent looked for other ways to get the drug. 41% had 
                                                          
65 FDA (2000): p. 1, s. 28 
66 FDA (2000): p. 1 
67 Schwarz A. (2013): “The Selling of Attention Deficit Disorder”, 
http://www.nytimes.com/2013/12/15/health/the-selling-of-attention-deficit-disorder.html?pagewanted=all 
[Accessed: 27th November 2015]. 
68 FDA (2008): p. 2, l. 10-12 
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gone to the doctor and got the prescription drug that were advertised for, 27% had gotten a free 
sample, for 26% were the drug not suited and 6% either refused, did not know, or looked for 
other ways to get the drug. All of the respondents were asked what they thought of the price 
for the advertised drug and 53% thought that the advertised drug were more expensive than the 
not advertised drug that could treat the same condition. 25% thought the price for advertised 
drugs and not advertised drugs were about the same, and 7% thought that the advertised drug 
were less expensive than a not advertised drug, where 14% did not know about the prices of 
the advertised drug and not advertised drug. The respondents where then asked if they read the 
safety and side-effects information, which is on the advertisements and 71% said yes, and 28% 
said no they did not. They were also asked what they thought of the information and 68% found 
it helpful, 15% found it frightening, 13% found it confusing, and 3% found it unnecessary69.  
 
Sum-up 
Pharmaceutical companies can market with Direct To Consumer Advertisements (DTCA), 
detailing, samples, educational and promotional meetings, and promotional mailings. The 
pharmaceutical companies have to obey the following laws made by the organization in 
authority, the Food and Drug Administration (FDA). The Direct To Consumer Advertisements 
(DTCA), cannot be misleading or false in all of the advertisements. If it is a help-seeking 
advertisement can only mention the symptoms of the disease, the name of the pharmaceutical 
company but not the actual drug to treat the disease. If it is a reminder advertisement, it can 
only mention the name of the drug but not which disease it treats. If it is a product claim 
advertisement, it mentions both the disease it treats and the drug who treats it, but has to 
mention both the risks and benefits of the drug.  
The pharmaceutical industry is the industry that spend the most on lobbying and are influencing 
both politicians and the FDA to loosen their regulation.  
A survey presented by the AARP, have shown that 91% of the respondents in the survey had 
seen a prescription drug advertisement, that 10% had gone to the doctor to ask for that drug 
after they have seen the advertisement, that 41% had gotten the drug they had asked for by the 
                                                          
69 Brown H. (2010): p. 4-17 
 
First Semester Project 
Sasha Scheele Sandberg 
Group 28 
 
24 
 
24 
doctor, that 53% thought that the price on the advertised drugs were more expensive than not 
advertised drugs, and that 71% read the safety and side-effect section on the advertisements.  
 
Discussion 
Pharmaceutical companies such as Shire, consists of and dispose of cultural, social and 
economic capital. If companies are to create symbolic capital and make a prescription drug 
desirable presented in the DTCAs, they have to draw from these capitals. The cultural capital 
pharmaceutical companies consist of is: knowledge, which the companies has gathered since 
it was founded (embodied), the drug, which the company is selling (objectified), and the 
companies name and reputation e.g. Shire, which might have a reputation of making misleading 
DTCAs (institutionalized). The social capital that the pharmaceutical companies consist of is 
the connections in its network that the company can collaborate with in order to be successful 
such as the FDA, politicians, marketing companies etc. The companies’ economic capital is 
their income or properties which they usually increase through selling their pharmaceutical 
drugs. Pharmaceutical companies invest money on lobbying, making DTCAs, promotional 
detailing, meetings etc. also to be able to gain economic capital.  
The amount symbolic capital which the pharmaceutical company are capable of acheving is 
therefore determined by its economic capital (the amount of money the company has gained) 
and its ability to trade this form of capital into other forms such as social capital (the 
connections which the company has gotten since the time the company was founded), and 
cultural capital, (the knowledge of the company, its workers, the drugs, and the name and 
reputation the company have). If a company has poor economic capital, the company cannot 
make expensive television advertisements and thereby have a hard time investing capital which 
can alter the structures in society to their favor. If a company has poor cultural capital it does 
not have the ability or know-how to produce or promote products efficiently. If a company has 
poor social capital, it does not have good contacts to promote through such as the media, 
politicians, or institutions like the FDA.  
The pharmaceutical companies’ habitus variates according to how big the pharmaceutical 
company is, the magnitude of its disposable capitals and the laws and restrictions which there 
are in the different states. And if these laws or rules are not respected the companies can be 
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brought to court. A company such as Shire, has been sent some warning letters because the 
company has been playing on the edge of the laws and been caught in it, such as making a 
YouTube video with the celebrity Ty Pennington, which was misleading.  
The rules the pharmaceutical companies has to obey depends on the states, though when 
marketing with DTCAs they have to obey the specific strict rules there are around help-seeking, 
reminder, and claim advertisements. The survey showed that the pharmaceutical companies 
were effective in reaching the consumers with 91% having seen this type of advertisement. The 
survey also showed that 10% of the people in the survey had gone to the doctor to ask for that 
specific prescription drug after they had seen the advertisement, which is 1 out of 10. The 
question then is, if these people really were sick to begin with or if the advertisement imposed 
this thought on them. Maybe these advertisements lead people to self-diagnose. Maybe people 
do not need to be informed about different diseases and drugs to cure them. Should people not 
just go to the doctor if they feel sick and let this professional decide on the cure? These 
questions are all debated in the U.S, and it could be that these are some of the consequences 
that DTCAs bring along. Though, one thing is sure and that is, that the pharmaceutical 
companies do have rules and laws which they have to act within, but at the same time they do 
also have a big influence on both FDA and politicians with their generous payments and are 
therefore not that restricted by the rules that they cannot change them by investing and 
transforming capital.  
 
Conclusion 
The pharmaceutical companies gain economic capital by making DTCAs and this requires that 
the pharmaceutical companies invest in lobbying significantly to impact both the FDA and 
politicians, so that they are not to be restricted by law making. The lobbying can have the 
consequence of the industry ending up with too loose regulations. The industry is effective in 
reaching the citizens with DTCAs. 91% have seen the advertisements, 53% think that the prices 
on the advertised drugs are more expensive than not advertised drugs, to treat the same disease, 
and 10% have gone to the doctor for the prescribed drug in the advertisement. The 
consequences of these advertisements can therefore be that more people believe that they are 
sick and that more begin to self-diagnose from advertisement information, that people are 
buying more expensive drugs than necessary to treat their disease, and that the industry is 
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spending too much money on these advertisements, which could have been used on producing 
life-saving medicine or research into new medicine.  
 
Perspectivation 
In this project I have investigated the pharmaceutical industry’s marketing and looked at how 
different forms of capital are used and the possible consequences of this process. To investigate 
this field further it would be interesting to look at why the consumers are so responsive to these 
advertisements. This would require interviews with many consumers in the U.S to explain this. 
It could be done by looking into a specific DTCA campaign and then look at the responses to 
this specific campaign. To make it even more narrow, look at a specific state that allows this 
campaign. This would make further research more specific and precise, but would also require 
access to the campaigns spending’s, the viewers exposed to the campaign, and a larger project.  
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Glossary 
 Brief summary: “The “brief summary” includes all the risk information about a 
prescription drug and is generally based on the prescribing information. The brief 
summary may leave out non-risk information, such as the chemical description of the 
drug, how it works in the body, and directions for using it. For DTC ads, we recommend 
that brief summaries be written in language that consumers can understand.”70 
 Fair balance: “This means that the content and presentation of a drug's most important 
risks must be reasonably similar to the content and presentation of its benefits. This 
does not mean that equal space must be given to risks and benefits in print ads, or equal 
time to risks and benefits in broadcast ads. The amount of time or space needed to 
present risk information will depend on the drug's risks and the way that both the 
benefits and risks are presented.”71 
 Major statement: “A “major statement” is required only for broadcast (TV, radio and 
telephone) ads. It consists of the drug's most important risks. The major statement must 
be presented in a clear, conspicuous, and neutral manner. The risks are generally 
similar to the risks required for “fair balance” in print ads.”72 
 Adequate provision: ““Adequate provision” applies only to broadcast ads. Broadcast 
ads must include either the "brief summary" or make "adequate provision" for the 
audience to find the drug's prescribing information. This requirement can be met by 
offering a variety of sources, including a healthcare provider, a toll-free telephone 
number, the current issue of a magazine containing a print ad for the drug, and a Web 
site address.”73 
 
                                                          
70 FDA: “Prescription Drug Advertising: Questions and Answers”, 
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/PrescriptionDrugAdvertising/ucm076768.htm#contro
l_advertisements [Accessed: 17th November 2015].  
71 FDA: “Drug Advertising: A Glossary of Terms”, 
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/PrescriptionDrugAdvertising/ucm072025.htm#fair_b
alance [Accessed: 12th November 2015]. 
72 FDA: “Prescription Drug Advertising: Questions and Answers”, 
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/PrescriptionDrugAdvertising/ucm076768.htm#contro
l_advertisements [Accessed: 17th November 2015]. 
73 FDA: “Prescription Drug Advertising: Questions and Answers”, 
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/PrescriptionDrugAdvertising/ucm076768.htm#contro
l_advertisements [Accessed: 17th November 2015]. 
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Appendix 
Summary 
This project uses Bourdieu’s theory of practice to investigate the pharmaceutical industry’s 
prescription drug promotion by looking at the pharmaceutical industry’s use of different forms 
of capitals. The project investigates the laws, the lobbying practice, Direct To Consumer 
Advertisement and examples of drug promotion in the U.S. The project shows that the 
pharmaceutical companies invest a lot of money on lobbying to affect the Food and Drug 
Administration and politicians in order to be able to promote prescription drugs in a manner 
that are beneficial to the pharmaceutical companies. The consequences is that the 
pharmaceutical companies becomes able to promote the pharmaceutical drugs with Direct To 
Consumer Advertisements which has increased the number of people consulting their doctors. 
This opens up for further debate about the social practice and impact of large corporations, 
which uses various means to improve their position in society.  
 
Study Portfolio  
● How is the theme of your house reflected in your project? 
  
The house theme is Media and Communication and I am reflecting this theme in my project 
through the processes in lawmaking there are in the pharmaceutical industry in the United 
States. This is covering the media as well as the lobbyism within the pharmaceutical industry.   
  
● What have you done to meet the study regulation's requirements to the project?   
  
In order to meet the study regulation’s requirements, I have shown with my project that I can 
use theory learned in class, exercise critical scientific judgement, and since this is a problem 
oriented project, I have used my project to show my abilities within the matter. Therefore, I 
have presented that I have gotten some general skills in the field of Social Science. 
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● Which experiences will you bring along to meet the academic requirements in your next 
semester's project? 
  
It have been difficult for us (in my previous group), to decide which direction our project should 
lean towards, due to different interests and work ambitions. I will in my next project talk about 
what ambition I have with the project and the academic level that I want the project to be at, 
along with which skills I have and that others have.  
  
● How have you organised your project work? 
 
My group has been changing since the beginning of the project work, with new people getting 
in the group and people dropping out of the group, and I have ended up writing the project 
alone. Though before I started working alone, the group was consisting of Amanda, Vytaute 
and I, where all of us did some reading about different areas, mostly Vytaute and I, and when 
we met to figure out what to do with our project, I came with suggestions for how we could 
narrow down our research, and told them what it should look like and how I wanted to do it. 
Vytaute did not what to change it said she disagreed with the suggestions I made. Amanda also 
had some suggestions of how the project should be like, though for me, the suggestions did not 
make sense. She wanted a project that would investigate if it was ethically okay to make Direct 
To consumer Advertisements and look at who is responsible for them. I did not think that our 
own opinion would not be scientific and therefore disagreed with her. This is just one example 
of the many directions in which we discussed. Vytaute and Amanda were usually agreeing with 
each other, while I were very consistent with what I thought could make a good project and 
what could not, and Amanda ended up saying she gives up arguing with me and just goes along. 
The two of them were then very mad at me, and espessially Vytaute, she did not even what to 
look me in the eye. At our supervisor meeting, our supervisor were then saying why have you 
changed the project again and did not remember that she had told us to change theory which 
would change the project. When I tried to explain what the theory was, she disagreed with how 
to use it, and thought you can only use Bourdieu’s theory of practice on people, which is not 
true. Maybe Bourdieu meant the theory on people but he never say that in his work, and there 
are examples of others using is theory on institutions as well. At the meeting, the supervisor 
got so frustrated that she began crying and said she could obviously see that the group project 
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work did not work out well, because Vytaute were also crying. The supervisor then told us and 
looked at me and said it is very important to compromise and work together. I believe that 
when making a project it should be the most logic solutions which should win the argument 
and not the compromise and were a little disappointed that she thought the problem was me, 
when she did not understand the situation completely. That was why I wanted to change my 
group. Though it was not me that actually ended up changing it, it was the group. They had 
heard from someone in the administration before I had gotten an official answer that I had 
decided to change group, so they kicked me out.   
  
● Which experiences will you bring along to succeed as an organizational unit in your 
next semester's project? 
 I have learned a lot of the experiences in the group work, about how to take control when 
others fail to make proper scientific work, about when to step out of something that is not 
working, and most of all I have been practicing my argumentation. I think this knowledge will 
be very useful in the future, when dealing with an organizational unit. I will bring along these 
experiences and off course, hope the group will function better, but I now know better how to 
deal with such situations.  
 
 
 
 
